Literature DB >> 6932525

Initial screening for carcinogenicity of commonly used drugs.

G D Friedman, H K Ury.   

Abstract

Computer-stored drug-dispensing data for 143,574 outpatients were used to identify users of various medicinal drugs during the 4-year period beginning in July 1969. These patients were followed through 1976 for the development of cancer. This report presents the results of screening analyses for 95 commonly used drugs and drug groups in relation to 56 primary cancer sites and combinations of sites. Statistically significant positive or negative associations with at least one site were found for 53 drugs. Some of these associations were undoubtedly due to chance sampling variation; some confirmed previous reports; some suggested interesting new hypotheses concerning possible drug effects or other etiologic or preventive factors. Further study is required before conclusions as to causality can be reached. Although the duration of follow-up in this study is relatively short so far, the absence of associations for many of the drugs studied provides some provisional assurance of their lack of carcinogenic effects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932525     DOI: 10.1093/jnci/65.4.723

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  25 in total

Review 1.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 2.  Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Authors:  Gary D Friedman; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

3.  Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.

Authors:  Louise R Howe; Scott M Lippman
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

4.  An epidemiologic study of thyroid cancer in Hawaii.

Authors:  L N Kolonel; J H Hankin; L R Wilkens; F H Fukunaga; M W Hinds
Journal:  Cancer Causes Control       Date:  1990-11       Impact factor: 2.506

5.  Identifying signals of interest when screening for drug-outcome associations in health care data.

Authors:  Anton Pottegård; Jesper Hallas; Shirley V Wang; Joshua J Gagne
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

6.  More questions than answers: antihistamines' link to cancer.

Authors:  A Robinson
Journal:  CMAJ       Date:  1994-09-15       Impact factor: 8.262

7.  Inhibition by indomethacin of spontaneous mammary tumorigenesis in SHN mice.

Authors:  H Nagasawa; T Naito
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

8.  Pharmaceuticals that cause mammary gland tumors in animals: findings in women.

Authors:  Gary D Friedman; Sheng-Fang Jiang; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Breast Cancer Res Treat       Date:  2008-07-16       Impact factor: 4.872

9.  Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.

Authors:  Powel H Brown; Kotha Subbaramaiah; Amoi P Salmon; Rebecca Baker; Robert A Newman; Peiying Yang; Xi Kathy Zhou; Reid P Bissonnette; Andrew J Dannenberg; Louise R Howe
Journal:  Cancer Prev Res (Phila)       Date:  2008-08

10.  The effects of tricyclic antidepressants on breast cancer risk.

Authors:  C R Sharpe; J-P Collet; E Belzile; J A Hanley; J-F Boivin
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.